Malignant neoplasms of nasopharynx ICD11 code: 2C3B.Z
Parenteral > General injections > IV: 50 mg per 5 mL ; 150 mg per 15 mL ; 450 mg per 45 mL ; 600 mg per 60 mL
Adolescents and adults
The recommendation is for this specific medicine
Patents have expired in most jurisdictions
Read more about patents.
Summary of evidence and Expert Committee recommendations
Carboplatin was originally added to the complementary list of the EML in 2009 as a treatment of advanced ovarian cancer. In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for carboplatin on the complementary list of the EML for use in treatment protocols for nasopharyngeal cancer was specifically endorsed. The relevant extract from TRS994 regarding the Expert Committee's consideration of treatment protocols for nasopharyngeal cancer is attached.